Dayra Therapeutics, Inc, founded in 2024, is making strides in the Biotechnology sector by developing oral macrocyclic peptide therapeutics aimed at treating a diverse array of human diseases. Setting itself apart, the company utilizes a combination of macrocycle discovery and computational modeling to design peptides that target specific disease-associated proteins.
This innovative approach positions Dayra Therapeutics as a key player in the field of precision medicine. Supporting its mission, the company recently secured a $70.00M early VC investment on 01 November 2025, with funding led by Versant Ventures—the same entity that founded Dayra through its Frontier Discovery Engine.
The latest capital injection underscores investor confidence in Dayra's potential to deliver groundbreaking therapies. As further developments unfold, Dayra Therapeutics remains a compelling prospect for investors seeking to back companies at the forefront of medical innovation.
